Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229

A Phase I, Open-Label, 2-Part Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism and Excretion of DA-1229 in Healthy Male Subjects

The objectives of this study are to evaluate the absolute bioavailability, and absorption and excretion of DA-1229, an IMP in clinical assessment for the treatment of T2DM. The oral and IV PK of DA-1229 will also be evaluated. The metabolism of DA-1229 may also be evaluated.

Inclusion Criteria:

• Healthy males
• Age 18 to 55
• BMI 18.0 to 30.0 kg/㎡

Exclusion Criteria:

• History of any drug or alcohol abuse in the past 2years
• Regular alcohol consumption nin males >21 units per week
• Current smokers and those who have smoked within the last 12months
• Radiation Exposure
• Positive drugs of abuse test result
• Positive HBsAg, HCV Ab, HIV results
• Serious adverse reaction or hypersensitivity to any drug of the formulation excipients
• Clinically significant allergy
• Donation of loss of blood within the previous 3 months
• Taking any prescribed or OTC drug or herbal remedies in the 14days before IMP administration